路易氏体失智症治疗市场－全球产业规模、份额、趋势、机会及预测（按分销管道、药物类型、地区和竞争格局划分，2021-2031年）

全球路易氏体失智症治疗市场预计将从 2025 年的 52.4 亿美元成长到 2031 年的 77.2 亿美元，复合年增长率为 6.67%。

该市场涵盖旨在控制由大脑中异常α-突触核蛋白沉积引起的复杂认知、运动和精神症状的药物和非药物干预措施。推动这一市场成长的关键因素是全球老年人口的不断增长以及由此导致的神经退化性疾病诊断数量的增加，这自然扩大了目标患者群体。此外，诊断生物标记的持续进步提高了早期区分痴呆症与其他类型失智症的能力，从而能够制定更及时的治疗策略，进一步促进了该领域的成长。

然而，市场扩张的一大障碍是误诊率高，因为其症状与阿兹海默症和帕金森氏症有显着重迭。这种诊断上的模糊性常常延误了适当治疗的启动，并阻碍了特定疗法的有效实施。根据阿兹海默症协会2024年的报告显示，约5%的老年失智症患者仅患有路易体失智症，这一数据凸显了将这类特定患者群体与更广泛的失智症患者群体中患有混合性疾病的患者区分开来的复杂性。

市场驱动因素

由于迫切需要疾病修正治疗（不仅缓解症状，还能改变潜在病理的治疗方法），强大的临床研发管线和加速的药物开发工作是市场扩张的关键驱动力。製药公司正在加强研究针对新型作用机制的药物，例如p38α激酶抑制剂，以解决与路易氏体相关的潜在突触功能障碍。随着后期临床试验的推进，潜在治疗方法正朝着监管部门的核准迈进，为传统上依赖仿单标示外用药的患者群体带来了希望。例如，2024年10月，CervoMed公司宣布其neflamapimod的RewinD-LB IIb期临床试验已完成最后一次患者访视，这标誌着针对该适应症的特异性治疗方法开发取得了重要里程碑式的进展。

公共和私人部门对神经系统疾病研究的投入不断增加，为高风险、高回报的药物研发计画提供了必要的资金，进一步巩固了市场成长。资金的增加支持了大规模的纵向研究和生物标记检验，为患者分层和提高临床试验成功率奠定了基础。一个显着的例子是宾州大学医学院于2024年9月宣布：美国国家老龄研究所（NIA）津贴1800万美元，用于研究路易氏体失智症认知衰退的原因和生物标记。鑑于该疾病对医疗保健系统带来的巨大经济负担，这些投资至关重要，它们促使支付方和医疗服务提供者探索有效的治疗方法。 2024年1月发表在《英国精神病学杂誌开放版》（BJPsych Open）上的一篇系统性回顾指出，路易氏体失智症（LBD）确诊后一年内，平均医疗费用上升至29174美元，凸显了开发有效临床解决方案的巨大经济价值。

市场挑战

全球路易氏体失智症治疗市场成长面临的主要障碍之一是误诊率高，这是由于其症状与阿兹海默症和帕金森氏症重迭。这种诊断上的模糊性显着限制了潜在市场，因为很大一部分患者接受的是其他神经退化性疾病的治疗，而非路易氏体失智症的特异性治疗。因此，製药开发商在确定合适的临床试验患者群体方面面临巨大挑战，从而延缓了标靶疗法的核准和商业化进程。无法准确筛选这类患者群体降低了製药企业的潜在投资回报，阻碍了研发进展，并限制了市场扩张。

这个问题实际上将很大一部分潜在基本客群隐藏起来，使市场参与企业难以触及。根据路易氏体失智症协会估计，到2024年，美国将有约140万人患有路易氏体失智症。这项统计数据表明，该疾病的实际盛行率与准确诊断的病例数之间存在严重脱节。只要这些患者仍未被识别或被错误地归类到更广泛的失智症患者群体中，市场就无法充分利用对路易体失智症特异性治疗方法的需求，从而直接抑制整体收入潜力。

市场趋势

将皮肤突触核蛋白生物标记应用于早期诊断，标誌着市场实践的重大变革，使该领域从依赖临床观察转向对活体患者进行客观的病理学检验。这一趋势解决了以往无法在不进行尸检的情况下确认α-突触核蛋白沉积的难题，从而能够更精准地识别临床试验和商业性治疗中的目标患者。 2024年5月，路易氏体失智症协会报告称，在由美国国立卫生研究院资助的Synuclein-One研究中，皮肤磷酸化α-突触核蛋白检测在临床诊断为路易氏体失智症的参与者中达到了96%的阳性检出率。如此高的诊断准确率对于将这些患者与单纯的阿兹海默症症患者准确区分开来至关重要，并确保新兴的标靶治疗能够惠及目标族群。

同时，市场正果断转向缓解疾病α-突触核蛋白免疫疗法，这类疗法旨在透过清除有毒蛋白聚集体来阻止神经退化，而不仅仅是控制症状。研发人员正优先开发主动疫苗策略，训练病患的免疫系统辨识并清除病理性寡聚物，从而防止其造成不可逆的神经元损伤。为了支持此策略的有效性，AC Immune公司于2024年11月公布了其II期VacSYn试验的中期结果，结果显示，其主动免疫疗法候选药物ACI-7104.056在三次给药后，与安慰剂相比，平均诱导了16倍更高的抗α-突触核蛋白抗体水平。这种作用机製表明，该疗法有可能延缓疾病进展，并有望彻底改变患者的长期治疗模式。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球路易氏体失智症治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依分销管道（医院药局、零售药局、药局、网路药局）
  • 依药物类型（胆碱酯酶抑制剂、抗精神病药物、碳度巴/左旋多巴、抗忧郁症、苯二氮平类药物、Modafinil）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美路易氏体失智症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲路易氏体失智症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区路易氏体失智症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲路易氏体失智症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲路易氏体失智症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球路易氏体失智症治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• BioArctic AB
• Eisai Co., Ltd
• Sumitomo Pharma Co., Ltd.
• Jazz Pharmaceuticals, Inc.
• Immungenetics ANoven Pharmaceuticals, Inc.
• Eli Lilly and Company
• Novartis AG
• Pfizer Inc.
• Mylan NV

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Lewy Body Dementia Treatment Market is projected to expand from USD 5.24 Billion in 2025 to USD 7.72 Billion by 2031, reflecting a compound annual growth rate of 6.67%. This market covers pharmacological and non-pharmacological interventions aimed at managing the intricate cognitive, motor, and psychiatric symptoms resulting from abnormal alpha-synuclein deposits in the brain. Key factors propelling this growth include the increasing global population of older adults and the corresponding rise in neurodegenerative diagnoses, which naturally widens the addressable patient base. Furthermore, the sector benefits from continuous advancements in diagnostic biomarkers, which improve the clinical ability to distinguish this condition from other dementias at earlier stages, thereby enabling more timely therapeutic strategies.

Conversely, a significant barrier to market progression is the high frequency of misdiagnosis due to substantial symptomatic overlap with Alzheimer's and Parkinson's diseases. This diagnostic ambiguity often delays appropriate care and restricts the effective deployment of specific treatments. As reported by the Alzheimer's Association in 2024, approximately 5% of older individuals with dementia show evidence of Lewy body dementia alone, a statistic that underscores the complex challenge of isolating this specific patient segment from those with mixed pathologies within the broader dementia population.

Market Driver

A robust clinical pipeline and accelerated drug development efforts serve as a primary catalyst for market expansion, driven by the urgent need for disease-modifying therapies rather than mere symptomatic relief. Pharmaceutical companies are increasingly targeting novel mechanisms of action, such as p38 alpha kinase inhibition, to address the underlying synaptic dysfunction associated with Lewy bodies. This intensification of late-stage clinical trials is bringing potential treatments closer to regulatory approval, offering hope for a patient population that has historically relied on off-label medications. For example, CervoMed reported in October 2024 the completion of the final patient visit in its RewinD-LB Phase 2b clinical trial for neflamapimod, marking a critical milestone in advancing specific therapeutics for this indication.

Market growth is further solidified by increasing public and private investment in neurological research, which provides the necessary capital for high-risk, high-reward discovery programs. Enhanced funding supports large-scale longitudinal studies and biomarker validation, which are essential for stratifying patient populations and improving trial success rates. A notable instance occurred in September 2024, when Penn Medicine announced that the National Institute on Aging awarded an $18 million grant to researchers to investigate the causes of cognitive decline and identify biomarkers in Lewy body diseases. These investments are crucial given the substantial economic burden the disease places on healthcare systems, incentivizing payers and providers to seek effective treatments; a systematic review in BJPsych Open in January 2024 highlighted that average medical costs rose to $29,174 in the first year following an LBD diagnosis, underscoring the immense financial value of developing effective clinical solutions.

Market Challenge

The primary obstacle hindering the growth of the Global Lewy Body Dementia Treatment Market is the high rate of misdiagnosis caused by symptomatic overlaps with Alzheimer's and Parkinson's diseases. This diagnostic ambiguity significantly restricts the addressable market, as a large proportion of patients are treated for other neurodegenerative conditions rather than receiving therapies specifically optimized for Lewy body dementia. Consequently, pharmaceutical developers face substantial hurdles in identifying suitable patient cohorts for clinical trials, which delays the approval and commercialization of targeted treatments. The inability to accurately segregate this patient population reduces the perceived return on investment for drug manufacturers, thereby stalling R&D progress and limiting market expansion.

This issue effectively conceals a massive segment of the potential customer base from market participants. According to the Lewy Body Dementia Association, an estimated 1.4 million individuals in the United States were affected by Lewy body dementia in 2024. This statistic reveals a profound gap between the actual prevalence of the disease and the number of accurately diagnosed cases. As long as these individuals remain unidentified or misclassified within the broader dementia population, the market cannot fully capitalize on the demand for specific Lewy body dementia interventions, directly impeding overall revenue potential.

Market Trends

The integration of cutaneous synuclein biomarkers for early diagnosis represents a critical evolution in market practice, shifting the sector from a reliance on clinical observation toward objective pathological validation in living patients. This trend resolves the historic difficulty of confirming alpha-synuclein deposition without post-mortem analysis, thereby enabling more accurate patient identification for clinical trials and commercial treatment. In May 2024, the Lewy Body Dementia Association reported that the NIH-funded Synuclein-One Study demonstrated that a cutaneous phosphorylated alpha-synuclein test achieved a 96% positive detection rate in participants clinically diagnosed with Lewy body dementia. Such diagnostic precision is essential for accurately segregating these patients from those with pure Alzheimer's disease, ensuring that emerging targeted therapies reach the correct demographic.

Simultaneously, the market is witnessing a decisive shift toward disease-modifying alpha-synuclein immunotherapies, which aim to halt neurodegeneration by clearing toxic protein aggregates rather than merely managing symptoms. Developers are prioritizing active vaccination strategies that train the patient's immune system to recognize and eliminate pathological oligomers before they cause irreversible neuronal damage. Validating this approach, AC Immune announced in November 2024 that interim results from the Phase 2 VacSYn trial showed the active immunotherapy candidate ACI-7104.056 induced anti-alpha-synuclein antibody levels on average 16-fold higher than placebo after three doses. This mechanism suggests a potential for slowing disease progression, fundamentally altering the long-term treatment landscape for affected individuals.

Key Market Players

• BioArctic AB
• Eisai Co., Ltd
• Sumitomo Pharma Co., Ltd.
• Jazz Pharmaceuticals, Inc.
• Immungenetics ANoven Pharmaceuticals, Inc.
• Eli Lilly and Company
• Novartis AG
• Pfizer Inc.
• Mylan N.V.

Report Scope

In this report, the Global Lewy Body Dementia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lewy Body Dementia Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Lewy Body Dementia Treatment Market, By Drug Type

• Cholinesterase Inhibitors
• Antipsychotic Drugs
• Carbidopa-Levodopa
• Antidepressants
• Benzodiazepine
• Modafinil

Lewy Body Dementia Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lewy Body Dementia Treatment Market.

Available Customizations:

Global Lewy Body Dementia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lewy Body Dementia Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies)
  • 5.2.2. By Drug Type (Cholinesterase Inhibitors, Antipsychotic Drugs, Carbidopa-Levodopa, Antidepressants, Benzodiazepine, Modafinil)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Lewy Body Dementia Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Distribution Channel
  • 6.2.2. By Drug Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lewy Body Dementia Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Distribution Channel
      • 6.3.1.2.2. By Drug Type
  • 6.3.2. Canada Lewy Body Dementia Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Distribution Channel
      • 6.3.2.2.2. By Drug Type
  • 6.3.3. Mexico Lewy Body Dementia Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Distribution Channel
      • 6.3.3.2.2. By Drug Type

7. Europe Lewy Body Dementia Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Distribution Channel
  • 7.2.2. By Drug Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lewy Body Dementia Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Distribution Channel
      • 7.3.1.2.2. By Drug Type
  • 7.3.2. France Lewy Body Dementia Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Distribution Channel
      • 7.3.2.2.2. By Drug Type
  • 7.3.3. United Kingdom Lewy Body Dementia Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Distribution Channel
      • 7.3.3.2.2. By Drug Type
  • 7.3.4. Italy Lewy Body Dementia Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Distribution Channel
      • 7.3.4.2.2. By Drug Type
  • 7.3.5. Spain Lewy Body Dementia Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Distribution Channel
      • 7.3.5.2.2. By Drug Type

8. Asia Pacific Lewy Body Dementia Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Distribution Channel
  • 8.2.2. By Drug Type
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lewy Body Dementia Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Distribution Channel
      • 8.3.1.2.2. By Drug Type
  • 8.3.2. India Lewy Body Dementia Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Distribution Channel
      • 8.3.2.2.2. By Drug Type
  • 8.3.3. Japan Lewy Body Dementia Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Distribution Channel
      • 8.3.3.2.2. By Drug Type
  • 8.3.4. South Korea Lewy Body Dementia Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Distribution Channel
      • 8.3.4.2.2. By Drug Type
  • 8.3.5. Australia Lewy Body Dementia Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Distribution Channel
      • 8.3.5.2.2. By Drug Type

9. Middle East & Africa Lewy Body Dementia Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Distribution Channel
  • 9.2.2. By Drug Type
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lewy Body Dementia Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Distribution Channel
      • 9.3.1.2.2. By Drug Type
  • 9.3.2. UAE Lewy Body Dementia Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Distribution Channel
      • 9.3.2.2.2. By Drug Type
  • 9.3.3. South Africa Lewy Body Dementia Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Distribution Channel
      • 9.3.3.2.2. By Drug Type

10. South America Lewy Body Dementia Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Distribution Channel
  • 10.2.2. By Drug Type
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lewy Body Dementia Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Distribution Channel
      • 10.3.1.2.2. By Drug Type
  • 10.3.2. Colombia Lewy Body Dementia Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Distribution Channel
      • 10.3.2.2.2. By Drug Type
  • 10.3.3. Argentina Lewy Body Dementia Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Distribution Channel
      • 10.3.3.2.2. By Drug Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lewy Body Dementia Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. BioArctic AB
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Eisai Co., Ltd
• 15.3. Sumitomo Pharma Co., Ltd.
• 15.4. Jazz Pharmaceuticals, Inc.
• 15.5. Immungenetics ANoven Pharmaceuticals, Inc.
• 15.6. Eli Lilly and Company
• 15.7. Novartis AG
• 15.8. Pfizer Inc.
• 15.9. Mylan N.V.

16. Strategic Recommendations

17. About Us & Disclaimer